RecruitingPhase 2NCT06819670

A Study to Prevent Infantile Spasms Relapse

A Multicenter Pilot Clinical Trial to Prevent Infantile Spasms Relapse

Sponsor

University of California, Los Angeles

Enrollment

40 participants

Start Date

May 5, 2025

Study Type

INTERVENTIONAL

Conditions

West Syndrome Infantile Spasms Infantile Epileptic Spasms Syndrome

Summary

After initially successful treatment, many children with infantile spasms unfortunately have a relapse, and relapse is linked to poor long-term outcomes such as autism and other forms of epilepsy. The aim of this study is to determine if treatment with low-dose prednisolone is safe, well tolerated, and effective in reducing the risk of relapse.

Eligibility

Min Age: 2 MonthsMax Age: 18 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Famotidine, a drug called Placebo, and others for people with infantile epileptic spasms syndrome, infantile spasms, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Months to 18 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.